

Convenience Translation

The text decisive for the invitation to the Annual General Meeting (AGM) of Heidelberg Pharma AG is the one written in German language.

Heidelberg Pharma AG
Ladenburg, Germany
German Securities Identification Number: A11QVV
ISIN: DE000A11QVV0

Unique identifier of the event: **DE000A11QVV0-GMET-202606**

Invitation to the virtual Annual General Meeting of Heidelberg Pharma AG

We hereby cordially invite our shareholders to the Annual General Meeting of Heidelberg Pharma AG, Ladenburg, Germany, which will take place on Tuesday, 23 June 2026 at 09:00 am (CEST) as a virtual Annual General Meeting without the physical presence of the shareholders or their authorized representatives, with the exception of the proxies appointed by the Company.

The venue of the meeting as defined by German Stock Corporation Act is the Company's registered office at Gregor-Mendel-Str. 22, 68526 Ladenburg, Germany. The shareholders and their authorized representatives (with the exception of the Company's proxies) will have neither the right nor the option to be physically present at the meeting venue. An audio and video broadcast of the entire Annual General Meeting will be available on the Internet for duly registered shareholders or their authorized representatives via the Company's website at <https://heidelberg-pharma.com/en/agm> via the password-protected Internet service (hereinafter the "AGM portal"). Shareholders – or their authorized representatives – will exercise their right to vote exclusively by means of electronic communication, namely by electronic postal vote or by authorizing and instructing the proxies appointed by the Company. For further details, please refer to the additional information and notes at the end of the invitation following the agenda.

Agenda

- 1. Presentation of the adopted annual financial statements of Heidelberg Pharma AG and the approved consolidated financial statements and the combined management report for Heidelberg Pharma AG and the Heidelberg Pharma Group, including the explanatory report of the Executive Management Board regarding the disclosures pursuant to Section 289 and Section 315a of the German Commercial Code (Handelsgesetzbuch, HGB) as well as the report of the Supervisory Board – in each case for the 2024/2025 fiscal year ended 30 November 2025**

The documents mentioned in agenda item 1 are available on the Internet at <https://heidelberg-pharma.com/en/agm>. The Supervisory Board approved the annual financial statements and the consolidated financial statements prepared by the Executive Management Board. Hence there is no need for the Annual General Meeting to adopt a resolution on this agenda item.

- 2. Resolution on the formal approval of the actions of the members of the Executive Management Board**

The Supervisory Board and the Executive Management Board propose formally approving the actions of the members of the Executive Management Board during the 2024/2025 fiscal year ended 30 November 2025.

- 3. Resolution on the formal approval of the actions of the members of the Supervisory Board**

The Executive Management Board and the Supervisory Board propose formally approving the actions of the members of the Supervisory Board during the 2024/2025 fiscal year ended 30 November 2025.

- 4. Resolution on the appointment of the auditor of the annual financial statements and the consolidated financial statements for the 2025/2026 fiscal year**

The Supervisory Board proposes, based on the recommendation of its Audit Committee, that Baker Tilly GmbH & Co. KG Wirtschaftsprüfungsgesellschaft, Düsseldorf, be appointed as auditor and group auditor for the 2025/2026 financial year.

The Audit Committee has declared that its recommendation is free from any undue influence by a third party and that no clause of the kind referred to in Article 16 (6) of the EU Statutory Audit Regulation (Regulation (EU) No 537/2014 of the European Parliament and of the Council of April 16, 2014) has been imposed on it that restricts the choice.

5. Resolution on the approval of the remuneration report

Pursuant to Section 162 (1) sentence 1 German Stock Corporation Act (AktG), the Executive Management Board and Supervisory Board of the listed company shall prepare a clear and comprehensible report each year on the compensation granted and owed to each individual current or former member of the Executive Management Board and Supervisory Board in the past financial year. Pursuant to Section 120a (4) German Stock Corporation Act (AktG), the Annual General Meeting of the listed company shall resolve on the approval of the compensation report.

The remuneration report of Heidelberg Pharma AG for the financial year 2024/2025, prepared in accordance with section 162 of the German Stock Corporation Act (AktG) and audited by the Company's auditor in accordance with section 162 (3) German Stock Corporation Act (AktG), together with the auditor's opinion, is available on the Company's website at <https://heidelberg-pharma.com/en/agm> from the time the Annual General Meeting is convened and also during the Annual General Meeting.

The Executive Management Board and the Supervisory Board propose that the remuneration report of Heidelberg Pharma AG for the 2024/2025 fiscal year, prepared and audited in accordance with section 162 German Stock Corporation Act (AktG), be approved.

6. Election of a new member of the Supervisory Board

At the Company's Annual General Meeting held on 15 May 2025, seven members were elected to the Supervisory Board under Agenda Item 7(a) through (g). The Supervisory Board member elected under Agenda Item 7(f), Dr. Dongzhou Jeffery Liu, has since been appointed to the Company's Executive Board and has resigned from the Supervisory Board. In accordance with the recommendation of its Personnel and Nominating Committee, the Supervisory Board proposes that the following person be elected as a member of the Supervisory Board to replace it, effective upon the conclusion of the Annual General Meeting:

Jack Ling

Residence: Hangzhou, China

Occupation: Deputy Director, Finance International Business Department at Huadong Medicine Co., Ltd.

Mr. Ling's election is in accordance with Section 10(6), sentence 1, of the Company's Articles of Association for the term ending at the close of the Annual General Meeting that decides on the discharge of the members of the Supervisory Board for the 2029 fiscal year (i.e., the 2030 Annual General Meeting).

The candidate proposed for election is neither a member of a statutory supervisory board at any company nor a member of a comparable domestic or foreign supervisory body of a business enterprise.

Detailed CVs of the candidate proposed is available for viewing on the Company's website at <https://heidelberg-pharma.com/en/agm>.

In accordance with the German Corporate Governance Code, the proposed candidate will ensure that he has sufficient time available to perform his duties; furthermore, the Supervisory Board has verified that the proposed candidate is able to commit the expected time required.

The proposed candidate is employed by Huadong Medicine Co., Ltd., Hangzhou, China (SZ 000963; Huadong), which holds 35% of the shares in the company.

7. Resolution on the amendment to the Articles of Association regarding the reduction of the size of the Supervisory Board

In connection with the extensive cost-cutting measures adopted by the Company in the last fiscal year, which included a reduction of the workforce by approximately 75%, the Supervisory Board has decided to reduce the number of its members from seven to five.

The Management Board and the Supervisory Board propose that the following resolutions be adopted:

- Section 10(1) of the Company's Articles of Association is amended as follows:
"(1) The Supervisory Board shall consist of five members."
- Section 11(5) of the Company's Articles of Association is amended as follows:
"(5) The Supervisory Board shall constitute a quorum if three of its members take part in the resolution. Absent members of the Supervisory Board may participate in the resolution by having written votes, which may also be transmitted as email attachments, submitted on their behalf by members of the Supervisory Board who are present or by a person designated in paragraph (8). Members joining via video or telephone conference shall participate in the resolution."

The amendments to the Articles of Association shall take effect upon entry in the Commercial Register.

The Company's website and the documents and information available there

This invitation to the virtual Annual General Meeting, the documents to be made available to the Annual General Meeting, the other information specified in Section 124a German Stock Corporation Act (AktG) and other information in connection with the Annual General Meeting will be available on the Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/agm> from the date on which the Annual General Meeting is convened.

Any shareholder counter-applications, shareholder nominations, and/or amendment proposals from shareholders received by Heidelberg Pharma AG that are required to be made public will likewise be made available at the website stated above. The final voting results will also be published there following the Annual General Meeting.

The website also provides access to the AGM portal for the virtual annual general meeting, which allows duly registered shareholders or their proxies to, among other things, exercise their voting rights by electronic absentee ballot or by granting a proxy and issuing instructions to the proxies appointed by the company, and enables such actions during the Annual General Meeting. Duly registered shareholders or their authorized representatives will be able to follow a live audio and video feed of the Annual General Meeting online in its entirety via the AGM portal on 23 June 2026 starting at 09:00 am (CEST) via electronic media.

**Total number of shares and voting rights
at the time this Annual General Meeting is convened**

The Company's share capital of EUR 46,784,317.00 is divided into 46,784,317 no par value bearer shares at the time the Annual General Meeting is convened. Each no par value share grants one vote. Consequently, there are 46,784,317 voting shares at the time the Annual General Meeting is convened. The Company does not hold any treasury shares at the time this Annual General Meeting is convened.

Holding the Annual General Meeting as a virtual Annual General Meeting without the physical presence of the shareholders and their authorized representatives; audio and video feed

The Management Board has decided that the Annual General Meeting will be held as a virtual Annual General Meeting without the physical presence of shareholders or their proxies, with the exception of the proxies appointed by the Company, in accordance with Section 15 (7) of the Company's Articles of Association.

Shareholders and their representatives (with the exception of the Company's proxies pursuant to Section 118a (2) sentence 4 in conjunction with Section 134 (3) sentence 5 German Stock Corporation Act (AktG) may therefore not physically attend the Annual General Meeting. For shareholders who have duly registered for the Annual General Meeting or their representatives, the entire Annual General Meeting will be broadcast by video and audio transmission on the website of Heidelberg Pharma AG at <https://heidelberg-pharma.com/en/agm> via the AGM portal. Instead of the conventional admission ticket, shareholders who have duly registered for the Annual General Meeting will be sent individual access data (access code and password) for the AGM portal, which they or their representatives can use to access AGM portal available on the website of Heidelberg Pharma AG at <https://heidelberg-pharma.com/en/agm>. The AGM portal will also be available to shareholders who have duly registered for the Annual General Meeting.

AGM portal for the Annual General Meeting

An AGM portal will be available on Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/agm> starting 2 June 2026. Following the procedures intended for that purpose, duly registered shareholders (and their authorized representatives, as applicable) will be able to use this area, among other things, to follow the audio and video feed of the Annual General Meeting, to exercise their voting rights, to authorize representatives, to submit questions, ask questions, propose motions and nominations, exercise their right to information pursuant to Section 131 German Stock Corporation Act (AktG), submit comments pursuant to Section 130a (1) to (4), exercise their right to speak or declare an objection to a resolution of the Annual General Meeting for the record or have their objections recorded in the minutes. In order to be able to use the AGM portal, they will need to log in using the unique access information that they receive after successfully registering and verifying their shareholdings.

The unique access information required for use of the AGM portal at <https://heidelberg-pharma.com/en/agm> will be sent out once registration is completed prior to the deadline; completed registration includes the Company's receipt of verification of shareholdings (see the following section "Conditions for participating in the Annual General Meeting and exercising shareholder rights, in particular voting rights") ("**AGM ticket**").

The use of the AGM portal by a proxy requires that the proxy receives the corresponding access data. Authorized intermediaries, shareholders' associations, proxy advisors and other persons treated as such by Section 135 (8) German Stock Corporation Act (AktG) may also use the AGM portal. The Company will provide them with electronic access upon request.

By using the AGM portal and clicking on the "Enter the Annual General Meeting" button during the Annual General Meeting on 23 June 2026, shareholders or their proxies will be connected electronically to the virtual Annual General Meeting. However, the electronic connection does not enable participation in the meeting within the meaning of Section 118 (1) sentence 2 German Stock Corporation Act (AktG) or the exercise of voting rights by way of electronic participation within the meaning of Section 118a (1) sentence 2 no. 2 German Stock Corporation Act (AktG).

Requirements for connecting to the Annual General Meeting and exercising shareholder rights, in particular voting rights

Pursuant to Article 15 (1) of the Articles of Association, those shareholders who register for the Annual General Meeting and provide proof of their shareholdings to the Company (**duly registered shareholders**) have the right to connect to the Annual General Meeting and to exercise their shareholder rights, in particular their voting rights, by means of electronic media. The registration and verification of shareholdings must be received by the Company by no later than the end of the day on

16 June 2026
(24:00 hours CEST)

at the following address, or e-mail address (e.g., as a scanned file in .pdf format):

Heidelberg Pharma AG
c/o meet2vote AG
Marienplatz 1
84347 Pfarrkirchen
Germany

Email: <mailto:anmeldung@meet2vote.de>

Verification of shareholdings prepared in text form by the last intermediary in the chain pursuant to Section 67c (3) of the German Stock Corporation Act shall suffice to demonstrate authorization. Such document must confirm share ownership as of the end of the 22nd day prior to the Annual General Meeting, i.e., by

1 June 2026
(24:00 hours CEST) (record date)

meet2vote AG is the Company's agent authorized to receive both the registrations and the evidence of shareholdings.

Upon timely receipt of the registration, including the verification of shareholdings, the relevant shareholders will be sent an AGM ticket with their personalized access details for using the AGM portal. We ask shareholders to register and submit their verification of shareholdings to the Company as early as possible.

Significance of the Record Date

The Record Date is the date that governs both the scope and the exercise of a shareholder's right to connect to and vote at the Annual General Meeting. Relative to the Company, a person shall only be considered a shareholder for the purpose of connecting to or exercising the voting right at the Annual General Meeting if they have verified their shareholdings by the Record Date. Persons who do not yet own any shares on the Record Date and only become shareholders after that date are not entitled to connect to the Annual General Meeting or vote, unless they hold a power of attorney or an authorization to exercise a right (see the section below entitled "Authorizing a third party to exercise voting and other rights"). Shareholders who have duly registered and verified their shareholdings may even connect to the Annual General Meeting and exercise their voting right if they sell their shares after the Record Date. The record date is not associated with a ban on selling the shares. The Record Date is not relevant to any right to participate in any dividends.

Exercising voting rights by electronic mail-in ballot

Duly registered shareholders may also cast their votes without participating in the Annual General Meeting by means of electronic communications (**mail-in ballot**).

Mail-in ballots can be submitted, changed or revoked by using the AGM portal accessible at <https://heidelberg-pharma.com/en/agm> following the procedures intended for that purpose.

This option of electronic mail-in voting will be available from 2 June 2026 until the time of closing of voting by the chairman of the meeting at the virtual Annual General Meeting on 23 June 2026. The same applies to a revocation or a change of the vote by electronic mail-in ballot.

Exercising voting rights by authorizing and instructing the proxies designated by the Company

The Company offers duly registered shareholders the option of authorizing proxies designated by the Company, who are then obligated to follow the shareholder's instructions.

A form for granting authorizations and issuing instructions will be sent to those shareholders together with the access information for the AGM portal accessible online at <https://heidelberg-pharma.com/en/agm>, and will also be available there for download.

Authorizations with instructions for the Company's designated proxies can be sent, changed or revoked by sending these by

22 June 2026

(24:00 hours CEST, (date of receipt))

to the following address, or e-mail address:

Heidelberg Pharma AG
c/o meet2vote AG
Marienplatz 1
84347 Pfarrkirchen
Germany

Email: hdpharma@meet2vote.de

or can be submitted, changed or revoked by using the AGM portal accessible at <https://heidelberg-pharma.com/en/agm> from 2 June 2026 following the procedures intended for that purpose. The date of receipt by the Company will be used to make any relevant determinations.

On the day of the virtual Annual General Meeting, authorizations with instructions for the Company's designated proxies can still be submitted, changed or revoked via the AGM portal at <https://heidelberg-pharma.com/en/agm> following the procedures intended for that purpose until the time when the chairman of the meeting closes the voting at the Annual General Meeting on 23 June 2026.

Where the Company's designated proxies have been authorized, instructions absolutely must be issued to them in order for voting rights to be exercised. The proxies are obligated to vote in accordance with their instructions. Without such express instructions, the proxies will not exercise the shareholder's voting rights.

Authorizing a third party to exercise voting and other rights

Shareholders may also have their voting rights and other rights exercised at the Annual General Meeting by duly appointed authorized representatives, e.g., by an intermediary, a shareholders' association, a voting rights advisor, or other individual of their choosing. This method also requires registration and the corresponding proof of ownership of the respective shares prior to the deadline. Appointed third parties can in turn exercise the voting rights by electronic mail-in ballot or by authorizing and instructing the Company's designated proxies (see above). Where the shareholder authorizes more than one individual, pursuant to Section 134 (3) sentence 2 German Stock Corporation Act, the Company may turn away one or more such appointees. This does not affect the option of appointing a separate proxy for shares in the Company held by a shareholder in different securities accounts.

If an authorization is not granted as set out in Section 135 German Stock Corporation Act, the appointment of an authorized representative or revocation of appointment as well as the proof of the appointment for the Company must be declared in "text form" (Section 126b German Civil Code).

A proxy form will be sent to duly registered shareholders together with the access information for the AGM portal accessible online at <https://heidelberg-pharma.com/en/agm>, and will also be available there for download.

Where intermediaries, shareholders' associations, voting rights advisors, or individuals or institutions deemed to have equivalent status as per Section 135 (8) German Stock Corporation Act are appointed as authorized representatives, the specific provisions of Section 135 apply, including the requirement that the authorization be retained in such a way that it can be verified. Consequently, exceptions to the general requirement of "text form" may apply. In certain circumstances, however, the respective appointees may stipulate specific rules for their own authorization. Shareholders are therefore urged to coordinate with the respective appointees in a timely manner, as applicable, regarding the particular form and procedure to be followed for their authorization.

The authorization can be declared directly to the appointee or to the Company. Proof of the authorization can be sent, changed or revoked by sending these by

22 June 2026

(24:00 hours CEST, (date of receipt))

to the following address, or e-mail address:

Heidelberg Pharma AG
c/o meet2vote AG
Marienplatz 1
84347 Pfarrkirchen
Germany
Email: hdpharma@meet2vote.de

or can be submitted, changed or revoked by using the AGM portal accessible at <https://heidelberg-pharma.com/en/agm> from 2 June 2026 following the procedures intended

for that purpose. The date of receipt by the Company will be used to make any relevant determinations.

On the day of the virtual Annual General Meeting, proxy appointments can only be submitted, changed or revoked by using the AGM portal accessible at <https://heidelberg-pharma.com/en/agm> by following the procedures intended for that purpose.

In order for a proxy to use the AGM portal, the proxy must receive the relevant access details.

Transmission of information via intermediaries via SWIFT

In addition to the above-mentioned methods of registration, proof of shareholding and the exercise of voting rights, registration, proof of shareholding and the granting of a proxy and instructions, as well as any amendments thereto, may also be effected via intermediaries via SWIFT in accordance with Section 67c of the German Stock Corporation Act (AktG). Authorised SWIFT participants should use

BIC: CPTGDE5WXXX

Instructions can only be sent via SWIFT in accordance with ISO 20022.

Registrations and proof of shareholding via SWIFT must be received by the Company no later than the final registration date (SWIFT Enrolment Market Deadline), i.e. by 16 June 2026, 24:00 (CEST). Changes or the granting of proxies and instructions via SWIFT are still possible after this date and must be received by the Company by 12:00 noon (CEST) on 22 June 2026 (SWIFT Vote Market Deadline).

Submission of comments

Shareholders or their representatives have the right pursuant to Art. 118a par. 1 sentence 2 no. 6 in conjunction with Art. 130a par. 1 to par. 4 German Stock Corporation Act (AktG) to make comments on the items on the agenda no later than five days before the virtual Annual General Meeting, i.e. by

17 June 2026
(24:00 hours CEST)

by means of electronic communication, via the AGM portal accessible at the Internet address <https://heidelberg-pharma.com/en/agm>, in accordance with the procedure provided for this purpose.

Comments are to be submitted in accordance with the procedure provided for this purpose in the AGM portal in text form in the file format PDF with a recommended file size of no more than 50 MB.

The comments submitted will be sent to all shareholders duly registered for the Annual General Meeting or their representatives, stating the name and place of residence or registered office of the shareholder or proxy submitting the comments, no later than four days before the meeting, i.e. by

18 June 2026
(24:00 hours CEST)

made available on the Company's website, unless this is permitted as an exception pursuant to Section 130a (3) sentence 4 German Stock Corporation Act (AktG). By submitting the statement, the shareholder or his proxy declares his consent to such disclosure.

Motions and election proposals, questions and objections to resolutions of the Annual General Meeting in the context of comments submitted in text form will not be considered at the Annual General Meeting; the submission of motions or election proposals, the exercise of the right to information and the lodging of objections to resolutions of the Annual General Meeting is only possible via the channels described separately in this invitation.

Right to speak

Shareholders or their representatives who are connected electronically to the Annual General Meeting have the right to speak at the Annual General Meeting by way of video communication. From approx. 1 hour before the start of the Annual General Meeting, a virtual table for requests to speak will be available via the AGM portal on the Company's website at <https://heidelberg-pharma.com/en/agm>, where shareholders or their representatives can register to speak. The right to speak also includes in particular the right to submit motions and election proposals in accordance with Section 118a (1) sentence 2 no. 3 German Stock Corporation Act (AktG) and the right to request information in accordance with Section 131 (1) German Stock Corporation Act (AktG).

Pursuant to Art. 16 par. 2 of the Company's Articles of Association, the Chairman of the Annual General Meeting may impose reasonable time limits on the shareholder's right to speak and ask questions and make more detailed provisions. In particular, the Chairman of the Annual General Meeting may set speaking and questioning times for the entire course of the Annual General Meeting, for individual items on the agenda and for individual speakers at the beginning of or during the course of the Annual General Meeting and, if necessary for the proper conduct of the Annual General Meeting, order the end of the debate.

The entire virtual Annual General Meeting, including video communication, is handled via the AGM portal using a system provided by our service provider. Shareholders or their representatives will require either a non-mobile device (PC, notebook, laptop) or a mobile device (e.g. smartphone or tablet) with one of the following browsers installed in the latest version: Microsoft Edge, Google Chrome, Mozilla Firefox or Safari. JavaScript must also be enabled. The use of other current browsers with the security settings recommended by the manufacturer is possible, but has not been tested. To speak, the devices must have a

camera and a microphone that can be accessed via the browser. No further installation of software components or apps on the end devices is required. Please ensure that you have a good, stable internet connection on your computer or mobile device and are using an up-to-date version of your browser. Persons who have registered for a speech via the virtual registration table will be activated for their speech in the AGM portal. The Company reserves the right to check the functionality of the video communication between the shareholder or proxy and the Company during the meeting and before the speech and to reject the speech if the functionality is not ensured.

Right to information Section 131 (1) German Stock Corporation Act

Pursuant to Section 131 (1) German Stock Corporation Act (AktG), each shareholder shall be provided with information by the Executive Board on the Company's affairs upon request at the Annual General Meeting to the extent that such information is necessary for a proper evaluation of the item on the agenda and no right to refuse information exists (right to information). The right to information is granted to shareholders in the virtual Annual General Meeting by means of electronic communication.

Section 131 (4) sentence 1 German Stock Corporation Act (AktG) stipulates that if a shareholder has been provided with information outside the Annual General Meeting due to his capacity as a shareholder, this information must be provided to any other shareholder or his proxy at his request in the Annual General Meeting, even if it is not necessary for the proper assessment of the item on the agenda.

In addition, Section 131 (5) sentence 1 German Stock Corporation Act (AktG) stipulates that if a shareholder is refused information, he may request that his question and the reason for which the information was refused be recorded in the minutes of the meeting.

Within the framework of the virtual Annual General Meeting, it is ensured that every shareholder who is electronically connected to the Annual General Meeting can submit the request pursuant to Section 131 (4) sentence 1 German Stock Corporation Act (AktG) and the request pursuant to Section 131 (5) sentence 1 German Stock Corporation Act (AktG) not only by way of video communication, i.e. within the framework of the right to speak and the procedure provided for this purpose (above "Right to speak"), but also by way of electronic communication via the AGM portal on the Company's website at <https://heidelberg-pharma.com/en/agm> in accordance with the procedures provided for this purpose with the corresponding access data in the Annual General Meeting.

Statement of objections on record

Properly registered shareholders or their representatives who are electronically connected to the Annual General Meeting may, from the beginning to the end of the Annual General Meeting, electronically file objections to resolutions of the Annual General Meeting for the record of the notary public via the AGM portal accessible at the Internet address <https://heidelberg-pharma.com/en/agm> in accordance with the procedure provided for this purpose. In addition, they also have the opportunity, within the scope of their right to speak, to declare an objection for the notary's minutes. The Company would like to point out once again that the proxies appointed by the Company do not accept instructions to file objections.

Motions to add items to the agenda submitted by a minority pursuant to Section 122 (2) German Stock Corporation Act

Shareholders whose shares together amount to one-twentieth of the share capital or the proportionate amount of EUR 500,000 of the Company's share capital (corresponding to 500,000 no-par value shares) may request that items be placed on the agenda and published. Each new item must be accompanied by a statement of reasons or a draft resolution. The request must be addressed in writing to the Executive Board of the Company and must be received by the Company at least 30 days prior to the Annual General Meeting, i.e. by the end of the

23 May 2026
(24:00 hours CEST)

at the following address:

Management Board of Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg
Germany

The applicants must prove that they have held the shares for at least 90 days prior to the date of receipt of the request and that they will hold the shares until the Executive Management Board's decision on the request, with Section 70 German Stock Corporation Act (AktG) applying when calculating the period of share ownership. The day of receipt of the request shall not be counted. A transfer from a Sunday, a Saturday or a public holiday to a preceding or following working day shall not be considered. Sections 187 to 193 of the German Civil Code shall not apply mutatis mutandis.

Additions to the agenda which are to be announced - insofar as they have not already been announced with the convening notice - will be published in the Federal Gazette without delay after receipt of the request and forwarded for publication to such media as can be expected to disseminate the information throughout the European Union. They will also be published on the internet at <https://heidelberg-pharma.com/en/agm> and communicated to the shareholders.

**Counter-applications pursuant to Section 126 (1)
and nominations pursuant to Section 127 German Stock Corporation Act (AktG)**

In addition, the Company's shareholders may send counter-applications to proposals of the Executive Management Board and/or the Supervisory Board concerning specific agenda items as well as nominations in connection with the election of Supervisory Board members or auditors. Counter-applications (including any supporting statement), shareholder nominations, and other shareholder requests regarding the Annual General Meeting are to be sent exclusively to the following address or e-mail address:

Heidelberg Pharma AG
c/o meet2vote AG
Marienplatz 1
84347 Pfarrkirchen
Germany
Email: antrag@meet2vote.de

Counter-applications and nominations that are sent to any other address shall not be considered. meet2vote AG has been officially designated to receive counter-applications and nominations on behalf of the Company.

All counter-applications and nominations received up to 14 days prior to the day of the Annual General Meeting, i.e., no later than by the end of the day on

8 June 2026
(24:00 hours CEST)

at the above-stated address, or e-mail address with proof of share ownership, including the name of the shareholder and any supporting statements to be made available, will be made available online to the other shareholders after their receipt at <https://heidelberg-pharma.com/en/agm>, provided the other conditions underlying the publication requirement under Section 126 German Stock Corporation Act have been met. Statements, if any, by the Company's management will also be posted at the aforementioned Internet address. Only counter-applications and nominations received by the end of the day on 8 June 2026 (24:00 hours CEST) will be deemed duly submitted for purposes of the virtual Annual General Meeting; counter-applications and nominations received after that point will be disregarded.

Aside from the reasons set forth in Section 126 (2) of the German Stock Corporation Act, the Executive Management Board also need not make an election proposal available if the proposal does not contain the candidate's name, profession and domicile. Proposals concerning the election of Supervisory Board members need not even be made available if they are not accompanied by information on the proposed candidate's appointments to other statutory supervisory boards as defined in Section 125 (1) sentence 5 of the German Stock Corporation Act.

Counter-applications or nominations for election submitted by shareholders or their authorized representatives which must be made available pursuant to Section 126 or Section 127 German Stock Corporation Act shall be deemed to have been made at the time they are made accessible. The Company allows the right to vote on these motions or election proposals to be exercised from this point in time. Motions from shareholders who have not duly registered or are not duly authorized do not have to be dealt with at the Annual General Meeting. Shareholders or their representatives who are connected to the Annual General Meeting also have the right to submit counter-applications or nominations in the meeting by way of video communication as part of their right to speak.

More information regarding shareholders' rights is available on the Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/agm>.

Data protection information for shareholders

Heidelberg Pharma AG processes personal information (name, address, e-mail address, number of shares, class of shares, how the shares are held, and number of the AGM ticket and access data to the AGM portal; name, address, and e-mail address and number of the AGM ticket and access data to the AGM portal of the shareholder representative designated by the respective shareholder, if applicable) on the basis of the applicable data privacy and protection laws so as to allow the shareholders to exercise their rights in connection with the virtual Annual General Meeting, and to comply with the provisions of law concerning an annual general meeting.

The processing of personal data of shareholders is absolutely necessary for them to connect to the virtual Annual General Meeting. Heidelberg Pharma AG is the data controller responsible for processing. Article 6 (1) c) of the General Data Protection Regulation (GDPR) is the legal basis for processing the data.

The service providers of Heidelberg Pharma AG that are commissioned for the purpose of organizing the virtual Annual General Meeting (particularly Annual General Meeting, IT, printing and shipping service providers) will receive only personal data from Heidelberg Pharma AG that is necessary for providing the commissioned service and process the data exclusively in accordance with the instructions of Heidelberg Pharma AG. In addition, the shareholders' data may be transmitted to authorities entitled to receive information. Your data will not be transferred to a country outside the EU.

Insofar as shareholders take advantage of the opportunity to submit questions in advance of the virtual Annual General Meeting and their questions are addressed there, they may be identified by name in this connection. Other participants of the virtual Annual General Meeting may learn this information. This data processing involving the identification of the respective shareholder by name is required in pursuit of our legitimate interests in creating a virtual Annual General Meeting that most closely approximates a physical annual general meeting. The legal basis for this processing is Article 6 (1) (f) GDPR.

As a rule, shareholders' personal data is deleted or anonymized as soon as it is no longer required for the aforementioned purpose and we are no longer obliged to retain it further in accordance with statutory documentation and retention requirements.

Shareholders have the right at any time to require information, the right to require the correction and restriction of data, the right to object to the use of data and the right to require the erasure of data in connection with the processing of your personal data, and a right to data transfer in accordance with Article 15 GDPR. You can exercise these rights vis-à-vis Heidelberg Pharma AG at no cost by sending an e-mail to

datenschutz@hdpharma.com

or by using the following contact information:

Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg, Germany

You also have the right to lodge a complaint with the data protection supervisory authorities pursuant to Art. 77 of the General Data Protection Regulation.

You can contact our Company's Data Protection Officer at:

Heidelberg Pharma AG
Data Protection Officer
Gregor-Mendel-Str. 22
68526 Ladenburg, Germany
E-mail: datenschutz@hdpharma.com

More information on data protection is available on the website of Heidelberg Pharma AG at <https://heidelberg-pharma.com/en/privacy-policy>.

Ladenburg, May 2026

Heidelberg Pharma AG
The Executive Management Board

Minimum information pursuant to Section 125(1) of the German Stock Corporation Act (AktG) in conjunction with Section 125 (5) AktG, Article 4 (1), and Table 3, Sections A through C of the Annex to Implementing Regulation (EU) 2018/1212

Type of Information	Description
A. Specification of the message	
1. Unique identifier of the event	DE000A11QVV0-GMET-202606
2. Type of message	Meeting notice of a General Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: NEWM]
B. Specification of the issuer	
1. ISIN	DE000A11QVV0
2. Name of issuer	Heidelberg Pharma AG
C. Specification of the meeting	
1. Date of the General Meeting	23.06.2026 [format pursuant to Implementing Regulation (EU) 2018/1212: 20260623]
2. Time of the General Meeting	09:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 07:00 UTC]
3. Type of the General Meeting	Ordinary General Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: GMET]
4. Location of the General Meeting	Virtual General Meeting: https://heidelberg-pharma.com/en/agm In accordance with the German Stock Corporation Act: Heidelberg Pharma AG, Gregor-Mendel-Str. 22, 68526 Ladenburg, Germany
5. Record Date	01.06.2026, 24:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 20260601; 22:00 UTC]
6. Uniform Resource Locator (URL)	https://heidelberg-pharma.com/en/agm